Description_x000D_ General description_x000D_ Erb-b2 receptor tyrosine kinase 2 (ErbB2) or human epidermal growth factor receptor 2 (HER2), is encoded by the gene mapped to human chromosome 17. The encoded protein belongs to the family of epidermal growth factors. ErbB2 membrane protein is characterized with a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane spanning region, and an intracellular tyrosine kinase domain.This protein does not have a ligand, and it either forms heterodimers with other family members or homodimer with itself when expressed at very high levels, to get activated. ErbB2 is expressed at low level in normal tissues, but at high level in breast cancer tissues._x000D_ Immunogen_x000D_ Peptide sequence around phosphorylation site of tyrosine1221/1222 (N-L-Y(p)-Y(p) -W), according to the protein ERBB2._x000D_ Target description_x000D_ Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF-alpha and amphiregulin._x000D_ Physical form_x000D_ Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol_x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ Erb-b2 receptor tyrosine kinase 2 (ErbB2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, over expression of this protein causes breast cancer. Heterodimer complex of ErbB2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of ErbB2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of ErbB2. This domain is missing in p95, a truncated form of ErbB2, and hence these cancer cells show resistance to trastuzumab. ErbB2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers._x000D_ Features and Benefits_x000D_ Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.